EDITORIAL SECTION

  • STRATEGY

    Smarter Pharma

    Quality management systems QMS are the backbone of pharmaceutical manufacturing ensuring safe products

  • EXPERT Talk

    Compliance to Competitive Advantage in Pharma Supply

    Compliance gets you through an audit Resilience gets medicines to patients on the day something unexpected happens The DSCSAs enhanced requirements took effect November but real interoperability required three more rounds of accommodation phased implementation with the smalldispenser

KNOWLEDGE BANK

  • Articles

    Understanding Pharmacodynamics: The Science behind Drug Action Mechanisms

    In the complicated world of pharmacology pharmacodynamics is also a place that is a bridge between chemistry and physiology Drugs do something somewhere and this explains how they do it In a simple way pharmacodynamics studies the action of drugs the effects of drugs in terms of their biochemical and physiological effects and how the effects are generated

    10 Essential Factors for Selecting a Pharma Publisher in Europe

    European pharmaceutical industry is one of the most progressive professional and productive industries in the world As it is understood researchers aspiring to publish novel papers are interested in credible pharma publishers Selecting appropriate publisher increases the visibility of your work and contributes to societal benefit but choosing wrong publisher decreases the value of your work This g...

    Access to Affordable Medicines: A Persistent Challenge for Europe

    The problem of affordable medicines has been topical in Europe for many years Despite the fact that there are well developed health units in many regions of the world and particularly in this continent the health challenges of the population have not been fully met especially in access to affordable basic medicines This problem is relevant not only to the patients but also to the stability of heal...

    B2B Pharma Magazines: Sponsored Thought Leadership Strategies for Brand Authority

    The pharmaceutical industry has never been short of innovation Every year brings breakthroughs in biologics advanced therapies AIdriven drug discovery manufacturing automation precision medicine and digital health

    Cybersecurity in Pharma: The Threat No One Budgeted For

    There is a particular kind of risk that organisations are bad at pricing the one that has never happened to them Pharmaceutical companies have spent a generation building sophisticated defences against the risks they know intimatelycontamination adulteration deviation recall Quality systems are mature inspectionready and deeply funded Cyber risk has never enjoyed that status It sat in the IT budge...

    Advertise Smarter with the 2025 Pharma Focus Europe Media Pack

    The internet has forever changed the healthcare industry and it is no longer whether to advertise but how to advertise better in the changing digital world Following the shift of pharma marketing to precision personalization and performance Pharma Focus Europe Media Pack is precisely your prescription to be the best in terms of competing in the European market

TOP ARTICLES

press releases Read more...

Monod Bio Licenses AI-designed Protein Technologies to SignalChem Biotech for Custom Discovery Assays

Monod Bio a Seattlebased AIenabled protein design company and SignalChem Biotech Inc a whollyowned subsidiary of Sino Biological Inc SZSE today announced a nonexclusive licensing agreement

Nxera Pharma’s Partner Neurocrine Biosciences Receives IND Acceptance from the FDA for Phase 2 Study of NBI-1117567 for Alzheimer's Cognition

Nxera Pharma Co Ltd Nxera or the Company TSE announces that its partner Neurocrine Biosciences Inc Neurocrine has received IND Acceptance from the US Food and Drug Administration

U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer

Revolution Medicines Inc a global commercialstage oncology company dedicated to discovering developing and delivering innovative medicines for patients with RASaddicted cancers

HepaRegeniX Receives Orphan Drug Designation for Darizmetinib for the Prevention of Post-Hepatectomy Liver Failure

HepaRegeniX GmbH a clinicalstage biotech company advancing novel therapies for acute and chronic liver diseases today announced that the US Food and Drug Administration FDA has granted Orphan Drug Designation

03 - 05

Sep 2026

5th MENA Congress for Rare Diseases 2026

Beach Rotana Hotel, Abu Dhabi,...

14 - 15

Sep 2026

16th American DDF Summit

Omni Boston Hotel at the Seapo...

15 - 17

Sep 2026

COPD Drug Development Summit 2026

Street, Boston, MA 02210, USA

21 - 23

Sep 2026

21 - 23

Sep 2026

Cancer R&D World Conference

Hilton Garden Inn Miami Dolphi...

22 - 23

Sep 2026

28 - 01

Sep 2026

LATEST NEWS Read more...

4basebio and Genezen Expand Collaboration on Synthetic DNA for Viral Vector Manufacturing

basebio PLC a specialist in enzymatically produced cellfree DNA for genetic medicines has expanded its collaboration with viral vector contract development and manufacturing organisation CDMO Genezen

Cronus Pharma Launches FDA-Approved Bioequivalent R

Cronus Pharma LLC has launched Robenacoxib Injection in the US offering an FDAapproved bioequivalent to ONSIOR robenacoxib Injection for veterinary use

Artis BioSolutions Launches mRNA and LNP Manufacturing Centre in Bilbao, Spain

Artis BioSolutions has launched its Genetic Medicines Centre of Excellence in Bilbao Spain expanding its development and manufacturing capabilities for genetic medicines

Lundbeck and EVERSANA Expand Partnership to Advance AI-Powered Commercialisation

Lundbeck a global pharmaceutical company focused on brain health and EVERSANA a provider of commercial services for the life sciences industry have announced a strategic partnership

Cambrex High Point Completes Regulatory Inspections to Support Commercial API Manufacturing

Cambrex a global contract development and manufacturing organisation CDMO has completed PreApproval Inspections PAIs at its High Point North Carolina facility by the US Food and Drug Administration FDA

ADARx Pharmaceuticals Receives FDA Fast Track Designation for Onvuzosiran for Hereditary Angioedema

ADARx Pharmaceuticals Inc has received Fast Track Designation from the US Food and Drug Administration FDA for onvuzosiran an investigational small interfering RNA siRNA therapy being developed to prevent attacks of hereditary angioedema HAE